Analysis of therapeutic targets for COVID 19-nCoV/SARS-CoV-2 and discovery by virtual screening methods

키워드

참고문헌 (70)

1. Apweiler R, "UniProt : the Universal Protein knowledgebase", Nucleic Acids Res, 32, pp.D115~D119 (2004)
2. Avorn J., "The $2.6 billion pill methodologic and policy considerations", N. Engl. J. Med ., 372, pp.1877~1879 (2015)
3. Barrows NJ, "A screen of FDA approved drugs for inhibitors of Zika virus infection", Cell Host. Microbe, 20, pp.259~270 (2016)
4. Chang CK, "Transient oligo merization of the SARS CoV N protein implication for virus ribonucleoprotein packaging", PLoS ONE, 8(3), pp.e65045~ (2013)
5. Chen H, "Interaction of the coronavirus nucleoprotein with nucleolar antigens and the host cell", J. Virol, 76, pp.5233~5250 (2002)
6. Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : a descript ive study", Lancet, 395, pp.507~513 (2020)
7. Chen X, "Thiopurine analogue inhibitors of severe acute respiratory syndrome coronavirus papain like protease, a deubiquitinating and deISGylating enzyme", Antivir. Chem. Chemother, 19, pp.151~156 (2009)
8. Cheng F, "Network based approach to prediction and population based validation of in silico drug repurposing", Nat. Commun, 9, pp.2691~ (2018)
9. Cheng F, "Individualized network based drug repositioning infrastructure for precision oncology in the panomics era", Brief Bioinformatics, 18, pp.682~697 (2017)
10. Cheng F, "Network based prediction of drug combinations", Nat. Commun, 10, pp.1197~ (2019)
11. Cheng F, "Prediction of drug target interactions and drug repositioning via network based inference", PLoS Comput. Biol, 8, pp.e1002503~ (2012)
12. Cheng F, "A genome wide positioning systems network algorithm for in silico drug repurposing", Nat. Commun, 10 (2019)
13. Cheng F, "Drug repurposing: new treatments for Zika virus infection?", Trends Mol. Med, 22(919), pp.921~ (2016)
14. Cheng F, "Systems biology based investigation of cellular antiviral drug targets identified by gene trap insertional mutagenesis", PLoS Comput. Biol, 12, pp.e1005074~ (2016)
15. Cheng F, "In silico oncology drug repositioning and polypharmacology", Methods Mol. Biol, 1878, pp.243~261 (2019)
16. Cheng KW, "Thiopurine analogs and mycophenolic acid synergistically inhi bit the papain like protease of Middle East respiratory syndrome coronavirus", Antivir. Res, 115, pp.9~16 (2015)
17. Coordinators NR, "Database resources of the National Center for Biotechnology Information", Nucleic Acids Res, 44, pp.D7~D19 (2016)
18. de Wilde AH, "Screening of an FDA approved compound library identifies four small molecule inhibitors of Middle East respiratory syndrome coronavirus replicati on in cell culture", Antimicrob. Agents Chemother, 58, pp.4875~ (2014)
19. de Wilde AH, "Host factors in coronavirus replication", Curr. Top. Microbiol. Immunol, 419, pp.1~42 (2018)
20. de Wit E, "SARS and MERS: recent insights into emerging coronaviruses", Nat. Rev. Microbiol, 14, pp.523~534 (2016)
21. Dyall J, "Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection", Antimicrob. Agents Chemother, 58, pp.4885~4893 (2014)
22. Dyall J, "Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies", Drugs, 77, pp.1935~1966 (2017)
23. Emmott E, "The cellular interactome of the coronavirus infectious bronchitis virus nucleocapsid protein and functional implications for virus biology", J. Virol, 87, pp.9486~9500 (2013)
24. Erlandson KM, "The impact of statin and angiotensin converting enzyme inhibitor", angiotensin receptor blocker therapy on cognitive function in adults with human imm unodeficiency virus infection, 2017, pp.65, 2042~2049
25. Fang J, "Network based translation of GWAS findings to pathobiology and drug repurposing for Alzheimer’s disease", MedRxiv, 60, pp.01~51 (2020)
26. Forni D, "Molecular evolution of human coronavirus genomes", Trends Microbiol, 25, pp.35~48 (2017)
27. Garcia CC, "The development of anti inflammatory drugs for infectious diseases", Discov. Med, 10, pp.479~488 (2010)
28. Gaulton A, "ChEMBL: a large scale bioactivity database for drug discovery", Nucleic Acids Res, 40, pp.D1100~D1107 (2012)
29. Greene JA, "Putting the patient back together social medicine, network medicine, and the limits of reductionism", N. Engl. J. Med, 377, pp.2493~2499 (2017)
30. He S, "Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C vi rus infection", Sci. Transl. Med, 7, pp.282~249 (2015)
31. Hong M, "Identification of a novel transcriptional repressor(HEPIS)that interacts with nsp 10 of SARS coronavirus", Viral Immunol, 21, pp.153~162 (2008)
32. Johansen LM, "FDA approved selective estrogen receptor modulators inhibit Ebola virus infection", Med, 5, pp.190~ (2013)
33. Josset L, "Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus", mBio, 4, pp.e00165~ (2013)
34. Karran P, "Thiopurines in current medical practice:molecular mechanisms and contributions to therapy related cancer", Nat. Rev. Cancer, 8, pp.24~36 (2008)
35. Kirchdoerfer RN, "Structure of the SARS CoV nsp12 poly merase bound to nsp7 and nsp8 co factors", Nat. Commun, 10, pp.2342~ (2019)
36. Ko C, "The FDA approved drug irbesartan inhibits HBV infection in HepG2 cells stably expressing sodium taurocholate co transporting polypeptide", Antivir. Ther, 20, pp.835~842 (2015)
37. Lamb J, "The Conn ectivity Map : using gene expression signatures to connect small molecules, genes, and disease", Science, 313, pp.1929~1935 (2006)
38. Lasso G, "A structure informed atlas of human virus interactions", Cell, 178, pp.1526~1541 (2019)
39. Li F, "Structure of SARS coronavirus spike receptor binding domain complexed with receptor", Science, 309, pp.1864~1868 (2005)
40. Li Q, "Early transmission dynamics in Wuhan, China, of novel coronavirus infected pneumonia", N Engl J Med, 382, pp.1199~ (2020)
41. Liu C, "Computational network biology: data, models, and applications", Phys. Rep, 846, pp.01~66 (2020)
42. Liu TQ, "BindingDB: a webaccessible database of experimentally determined protein ligand binding affinities", Nucleic Acids Res, 35, pp.D198~D201 (2007)
43. Lu R, "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding", Lancet, 395, pp.565~574 (2020)
44. McNulty S, "Host mTORC1 signaling regulates andes virus replication", J. Virol, 87, pp.912~922 (2013)
45. Moskowitz DW, "The central role of angiotensin I converting enzyme in vertebrate pathophysiology", Chem, 4, pp.1433~1454 (2004)
46. Paules CI, "Coronavirus infections more than just the common cold", JAMA, 323, pp.707~708 (2020)
47. Pawson AJ, "The IUPHAR", BPS Guide to PHARMACOLOGY: an expertdriven knowledgebase of drug targets and their ligands, 2014, pp.42, D1098~D1106
48. Rainsford KD, "Influenza (“Bird Flu”), inflammation and anti inflammatory", analgesic drugs, 2006, pp.14, 2~9
49. Reghunathan R, "Expression profile of immune response genes in patients with severe acute respiratory syndrome", BMC Immunol, 6, pp.01~11 (2005)
50. Santos R, "A comprehensive map of molecular drug targets", Nat. Rev. Drug Discov, 16, pp.19~34 (2017)
51. Seko Y., "Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3", Clin. Sci, 110, pp.379~386 (2006)
52. Silvestri M, "Melatonin: its possible role in the management of viral infections a brief review", Ital. J. Pediatr, 39, pp.61~ (2013)
53. Sirota M, "Discovery and preclinical validation of drug indications using compendia of public gene expression data", Sci. Transl. Med, 3, pp.96~ (2011)
54. Smith IN, "Conformational dynamics and allosteric regulation landscapes of germline PTEN mutations associated with autism compared to those associated with cancer", Am. J. Hum. Genet, 104, pp.861~878 (2019)
55. Srinivasan V, "Melatonin in bacterial and viral infections with focus on sepsis: a review", Recent Pat. Endocr. Met ab. Immune Drug Discov, 6, pp.30~39 (2012)
56. Stöhr S, "Host cell mTORC1 is required for HCV RNA replication", Gut, 65, pp.2017~2028 (2016)
57. V'kovski P, "Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity labeling", eLife, 8, pp.e42037~ (2019)
58. Wang CH, "Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure", Crit. Care Med, 42, pp.313~321 (2014)
59. Wang XJ, "Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepati tis B virus entry by disturbing Na(+) dependent taurocholate cotransporting polypeptide activity", Antivir. Res., 120, pp.140~146 (2015)
60. Wrapp D, "Cryo EM structure of the 2019 nCoV spike in the prefusion conformation", Science, 03, pp.1260~1263 (2020)
61. Xu M, "Identification of small molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen", Nat. Med, 22, pp.1101~1107 (2016)
62. Yang H, "Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information", Nucleic Acids Res, 44, pp.D1069~D1074 (2016)
63. Yang S, "Understanding human virus protein protein interactions using a human protein complex based analysis framework", mSystems, 4, pp.e00303~ (2019)
64. Yuan S, "SREBP dependent lipidomic reprogramming as a broadspectrum antiviral target", Commun, 10, pp.120~ (2019)
65. Zeng X, "deepDR : a network based deep learning approach to in silico drug repositioning", Bioinformatics, 35, pp.5191~5198 (2019)
66. Zeng, X, "Network based prediction of drug target interactions using an arbitrary order proximity embedded deep forest", Bioinformatics, 10, pp.01~23 (2020)
67. Zeng, X., "Target identification among known drugs by deep learning from heterogeneous networks", Chem. Sci, 11, pp.1775~1797 (2020)
68. Zhao, Y., "Toremifene interacts with and destabilizes the Ebola virus glycoprotein", Nature, 535, pp.169~172 (2016)
69. Zhou P, "A pneumonia outbreak associated with a new coronavirus of probable bat origin", Nature, 579, pp.270~273 (2020)
70. Zumla A, "Coronaviruses drug discovery and therapeutic options", Nat. Rev. Drug Discov, 15, pp.327~347 (2016)

관련 논문AI추천